X4 Pharmaceuticals to Announce Q2 2024 Financial Results and Host Call on August 8, 2024

BOSTON, July 30, 2024 – X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company dedicated to improving the lives of individuals with rare immune system diseases, has announced that it will release its financial results for the second quarter, which ended on June 30, 2024, on Thursday, August 8, 2024. In conjunction with this release, the company will also provide corporate updates and host a conference call and webcast at 8:30 a.m. ET on the same day.

To participate in the conference call, interested parties in the United States can dial 1-800-225-9448, while international participants can dial 1-203-518-9708. The conference ID required for access is X4PHARMA. Additionally, the live webcast will be available through the investor relations section of the X4 Pharmaceuticals website. For those unable to attend the live session, a replay of the webcast will be accessible on the company's website following the completion of the call.

X4 Pharmaceuticals is committed to delivering progress for patients by developing and commercializing new therapies aimed at rare immune system diseases with significant unmet needs. Their expertise in CXCR4 and immune system biology has led to the successful development of mavorixafor, which has been approved in the U.S. under the brand name XOLREMDI™ (mavorixafor) capsules for its initial indication. X4 is also exploring additional potential indications for mavorixafor.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!